-
Scientists from the Radboud University Medical Center in Nijmegen, the Netherlands; the University of Sydney in Sydney, Australia; and St. Vincent's Hospital and the University of Melbourne in Melbourne, Australia, recently put together research about people being afraid that their cancer will return when they receive treatment customized just for them.
-
AstraZenica said it presented positive results of the Phase III OlympiAD trial of Lynparza (olaparib) on patients with HER2-negative gBRCA-mutated metastatic breast cancer at the 2017 American Society of Clinical Oncology (ASCO) meeting in Chicago, and the results were also published in the New England Journal of Medicine.
-
A recent study by researchers from the American Cancer Society indicates patients who have regular screenings since implementation of Affordable Care Act (ACA) are more likely to be diagnosed at the earliest, most treatable stage of four types of cancers, a posting on the American Society of Clinical Oncology website said.
-
The American Society of Clinical Oncology (ASCO) said results of a Phase III clinical trial of the targeted therapy gefitinib in patients with epidermal growth factor receptor (EGFR)-positive, stage II-IIIA non-small cell lung cancer (NSCLC) showed it was more effective in preventing recurrence after lung cancer surgery than chemotherapy.